Glucagen + Mayne Glucagon

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hypoglycemia

Conditions

Hypoglycemia

Trial Timeline

Aug 1, 2007 → Mar 1, 2008

NCT ID

NCT00745186

About Glucagen + Mayne Glucagon

Glucagen + Mayne Glucagon is a phase 1 stage product being developed by Pfizer for Hypoglycemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00745186. Target conditions include Hypoglycemia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00745186	Phase 1	Completed	Aug 1, 2007	Mar 1, 2008	Hypoglycemia

Competing Products

20 competing products in Hypoglycemia

See all competitors

Product	Company	Stage	Hype Score
MBX 1416 (INN imapextide)	MBX Biosciences	Phase 2	47
MBX 1416 (Part A) + MBX 1416 (Part B) + Placebo + MBX 1416 (Part C)	MBX Biosciences	Phase 1	28
Nasal Glucagon	Eli Lilly	Phase 3	77
Glucagon + Insulin	Abvance Therapeutics	Phase 1	25
Nasal Glucagon + Intramuscular Glucagon	Eli Lilly	Phase 1	33
Nasal Glucagon 1 mg + Nasal Glucagon 2 mg + SC Glucagon + Nasal Glucagon 3 mg	Eli Lilly	Phase 2	52
Nasal Glucagon	Eli Lilly	Phase 3	77
Eplerenone + Placebo	Johnson & Johnson	Pre-clinical	23
Sitagliptin phosphate + Placebo	Merck	Approved	85
Pasireotide	Novartis	Phase 1	33
Dasiglucagon	Novo Nordisk	Phase 3	76
Pramlintide	Bristol Myers Squibb	Approved	84
dasiglucagon + placebo + GlucaGen HypoKit	Zealand Pharma	Phase 3	74
Dasiglucagon + Placebo	Zealand Pharma	Phase 1	30
Dasiglucagon + Dasiglucagon + Placebo	Zealand Pharma	Phase 2	49
ZP4207 + Glucagon	Zealand Pharma	Phase 1	30
ZP4207 + Placebo	Zealand Pharma	Phase 1	30
Dasiglucagon + Placebo	Zealand Pharma	Phase 3	74
dasiglucagon + GlucaGen	Zealand Pharma	Phase 3	74
Dasiglucagon + Placebo	Zealand Pharma	Phase 2	49

Other Products from Pfizer